Preoperative prediction of very early recurrence (within 6 months) following resection for intrahepatic cholangiocarcinoma and development of personalized neoadjuvant therapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036558

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrahepatic cholangiocarcinoma

Interventions

1:Neoadjuvant therapy

2:contrast

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Clinical diagnosis of intrahepatic RHCC; (2) Absence of macroscopic vascular invasion or extrahepatic distant metastasis; (3) Age between 18 and 75 years; (4) ECOG score 0-1; (5) Child-Pugh grade A liver function, no esophageal varices or ascites, a platelet count > 50 x 10^9/L, and a prothrombin time prolongation < 5 seconds.

Exclusion criteria

Exclusion criteria: (1) A history of other malignancies within the past 5 years before inclusion; (2) A history of any anti-cancer treatment before inclusion; (3) A history of spontaneous tumor rupture; (4) A history of cerebrovascular accident within the past 6 months before inclusion; (5) A history of unstable angina pectoris, myocardial infarction or heart failure within the past 6 months before inclusion; (6) A history of surgical treatment for other diseases within the past 4 weeks before inclusion; (7) Severe lung diseases (e.g. pulmonary fibrosis, severe emphysema, pulmonary heart disease); or forced expiratory volume in 1 second (FEV1) 50 mmHg; (8) Serum creatinine > 1.25 times of normal upper limit; (9) Poorly-controlled acute or active infections (infectioninduced fever > 38 degrees C); (10) Poorly-controlled hypertension or diabetes; (11) Severe mental diseases or disorders; (12) Receiving systematic administration of corticosteroids; (13) Requirement of concomitant surgical treatment for other diseases; (14) Women during pregnancy or breast-feeding; (15) Other serious underlying diseases; (16) Patients who are unable or refuse to comply with the treatment and monitoring required by the study; (17) Participation in other clinical trials; (18) Refusal to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Recurrence with 6 months;	—

Countries

China

Contacts

Public ContactWu Lu

Eastern Hepatobiliary Surgery Hospital

electchina@hotmail.com+86 13524303004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026